Table 1

Patient demographics and diseasecharacteristics at baseline
KRAS PRO analysis set PRO analysis set
WT KRAS (n= 76) MT KRAS (n= 54) Overall (n= 137)
Sex, n (%)
  Male 61 (80) 29 (54) 95 (69)
  Female 15 (20) 25 (46) 42 (31)
Race/ethnicity, n (%)
  White/Caucasian 73 (96) 53 (98) 133 (97)
  Black/African American 2 (3) 0 (0) 2 (1)
  Hispanic/Latino 0 (0) 1 (2) 1 (1)
  Japanese 1 (1) 0 (0) 1 (1)
Median age, years (range) 63.5 (21–84) 65.0 (37–80) 64.0 (21–84)
Age group, n (%)
  <65 years 40 (53) 26 (48) 71 (52)
  ≥65 years 36 (47) 28 (52) 66 (48)
  <75 years 71 (93) 44 (81) 121 (88)
  ≥75 years 5 (7) 10 (19) 16 (12)
Primary tumour type, n (%)
  Colon cancer 43 (57) 36 (67) 82 (60)
  Rectal cancer 33 (43) 18 (33) 55 (40)
Number of metastatic sites, n (%)
  1 33 (43) 23 (43) 63 (46)
  2 22 (29) 19 (35) 41 (30)
  ≥3 21 (28) 12 (22) 33 (24)
Location of metastatic sites, n (%)
  Liver only 28 (37) 15 (28) 46 (34)
  Liver plus other sites 35 (46) 25 (46) 60 (44)
  Other sites only 13 (17) 14 (26) 31 (23)
ECOG performance status, n (%)
  0 43 (57) 30 (56) 80 (58)
  1 30 (39) 20 (37) 50 (36)
  2 3 (4) 4 (7) 7 (5)
Mean (SD) PRO scores
  EQ-5D health state index 0.81 (0.22) 0.80 (0.22) 0.81 (0.22)
  EQ-5D overall health rating 71.7 (20.1) 71.9 (19.6) 72.5 (19.8)
  QLQ-C30 global health status 64.4 (22.5) 65.1 (22.8) 65.8 (22.5)

ECOG Eastern Oncology Group; PRO patient-reported outcome.

Thaler et al.

Thaler et al. BMC Cancer 2012 12:438   doi:10.1186/1471-2407-12-438

Open Data